Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$946K Sell
33,704
-1,326
-4% -$35.3K 0.05% 324
2025
Q4
$872K Sell
35,030
-4,097
-10% -$103K 0.04% 348
2025
Q3
$997K Buy
39,127
+3,898
+11% +$96.2K 0.05% 256
2025
Q2
$854K Sell
35,229
-15,738
-31% -$367K 0.06% 244
2025
Q1
$1.29M Buy
50,967
+2,348
+5% +$61.4K 0.11% 142
2024
Q4
$1.29M Buy
48,619
+973
+2% +$26.4K 0.12% 129
2024
Q3
$1.38M Sell
47,646
-4,979
-9% -$145K 0.12% 128
2024
Q2
$1.47M Buy
52,625
+772
+1% +$21.3K 0.14% 112
2024
Q1
$1.44M Sell
51,853
-77,035
-60% -$2.14M 0.14% 113
2023
Q4
$3.71M Buy
128,888
+98,405
+323% +$2.97M 0.16% 90
2023
Q3
$1.01M Buy
+30,483
New +$1.08M 0.13% 104

Other funds holding PFE

Syon Capital's PFE Position: Q1 2026 in Review

Syon Capital reduced its Pfizer (PFE) stake by 3.8% in Q1 2026, selling an estimated $35.3K and leaving 33,704 shares worth $946K. The position accounts for 0.05% of the portfolio, ranked #324.

Syon Capital first reported a position in PFE in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.71M in Q4 2023. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Syon Capital held 33,704 shares of Pfizer worth $946K as of Q1 2026.
  • Syon Capital sold 1,326 Pfizer shares in Q1 2026, an estimated $35.3K.
  • Pfizer made up 0.05% of Syon Capital's portfolio in Q1 2026, its #324 holding.
  • Syon Capital first reported a position in Pfizer in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's Pfizer position peaked at $3.71M in Q4 2023.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.